JP2014532649A5 - - Google Patents

Download PDF

Info

Publication number
JP2014532649A5
JP2014532649A5 JP2014538974A JP2014538974A JP2014532649A5 JP 2014532649 A5 JP2014532649 A5 JP 2014532649A5 JP 2014538974 A JP2014538974 A JP 2014538974A JP 2014538974 A JP2014538974 A JP 2014538974A JP 2014532649 A5 JP2014532649 A5 JP 2014532649A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
monoclonal antibody
antibody according
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014538974A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014532649A (ja
JP6316195B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/061782 external-priority patent/WO2013063186A2/en
Publication of JP2014532649A publication Critical patent/JP2014532649A/ja
Publication of JP2014532649A5 publication Critical patent/JP2014532649A5/ja
Application granted granted Critical
Publication of JP6316195B2 publication Critical patent/JP6316195B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014538974A 2011-10-26 2012-10-25 モノクローナル抗体および使用の方法 Active JP6316195B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161551918P 2011-10-26 2011-10-26
US61/551,918 2011-10-26
US201261699300P 2012-09-11 2012-09-11
US61/699,300 2012-09-11
PCT/US2012/061782 WO2013063186A2 (en) 2011-10-26 2012-10-25 Monoclonal antibodies and methods of use

Publications (3)

Publication Number Publication Date
JP2014532649A JP2014532649A (ja) 2014-12-08
JP2014532649A5 true JP2014532649A5 (https=) 2016-02-12
JP6316195B2 JP6316195B2 (ja) 2018-04-25

Family

ID=48168777

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014538974A Active JP6316195B2 (ja) 2011-10-26 2012-10-25 モノクローナル抗体および使用の方法

Country Status (8)

Country Link
US (3) US9790280B2 (https=)
EP (3) EP3378489A1 (https=)
JP (1) JP6316195B2 (https=)
AU (1) AU2012328819B2 (https=)
BR (1) BR112014010008A2 (https=)
CA (1) CA2853637C (https=)
RU (1) RU2623122C2 (https=)
WO (1) WO2013063186A2 (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012328819B2 (en) * 2011-10-26 2017-08-03 Elanco Tiergesundheit Ag Monoclonal antibodies and methods of use
JP6595458B2 (ja) 2013-09-20 2019-10-23 ブリストル−マイヤーズ スクイブ カンパニー 腫瘍を処置するための抗lag−3抗体と抗pd−1抗体との組合せ
CN106029697B (zh) 2013-12-20 2021-06-04 英特维特国际股份有限公司 具有经修饰的ch2-ch3序列的犬抗体
SG11201605203UA (en) 2013-12-24 2016-07-28 Argen X N V Fcrn antagonists and methods of use
CN107074952B (zh) 2014-09-30 2021-04-09 英特维特国际股份有限公司 结合犬pd-l1的pd-l1抗体
CA2978253A1 (en) * 2015-03-09 2016-09-15 Argenx Bvba Methods of reducing serum levels of fc-containing agents using fcrn antagonists
US11091556B2 (en) 2015-12-18 2021-08-17 Intervet Inc. Caninized human antibodies to human IL-4R alpha
CA3005696A1 (en) 2015-12-18 2017-06-22 Intervet International B.V. Caninized human antibodies to human and canine il-4r alpha
KR102131544B1 (ko) 2016-02-18 2020-07-07 엘랑코 유에스 인코포레이티드 키메라 개 항-cd20 항체
ES2965352T3 (es) 2017-05-30 2024-04-12 Bristol Myers Squibb Co Tratamiento de tumores positivos a gen 3 de activación de linfocitos (LAG-3)
CN110678200B (zh) 2017-05-30 2024-05-17 百时美施贵宝公司 包含抗lag-3抗体或抗lag-3抗体和抗pd-1或抗pd-l1抗体的组合物
US12297272B2 (en) 2017-08-15 2025-05-13 Eianco US inc. IgG Fc variants for veterinary use
CA3081144A1 (en) 2017-12-08 2019-06-13 Argenx Bvba Use of fcrn antagonists for treatment of generalized myasthenia gravis
US12202900B2 (en) 2018-06-08 2025-01-21 argenx BV Compositions and methods for treating immune thrombocytopenia
US20210388053A1 (en) * 2018-10-18 2021-12-16 Kindred Biosciences, Inc. Fc Variants with Altered Binding to Neonatal Fc Receptor (FCRN) for Veterinary Use
CN120904316A (zh) * 2018-12-27 2025-11-07 伊兰科美国公司 兽用IgG Fc变体
JP7565951B2 (ja) 2019-06-07 2024-10-11 アルジェニクス ビーブイ 皮下投与に好適なFcRnインヒビターの医薬製剤
JP2021059499A (ja) * 2019-10-03 2021-04-15 日本全薬工業株式会社 イヌcd20に対するモノクローナル抗体又は抗体フラグメント
JP2023509195A (ja) 2020-01-08 2023-03-07 アルジェニクス ビーブイ 天疱瘡症を治療する方法
WO2021165417A1 (en) 2020-02-19 2021-08-26 Adivo Gmbh Modified fc regions
MX2022013840A (es) * 2020-05-04 2023-02-09 Inhibrx Inc Polipéptidos de unión a pd-1 canina y usos de los mismos.
US20220024904A1 (en) * 2020-07-06 2022-01-27 Research Foundation Of The City University Of New York Reagent for bioconjugation via irreversible rebridging of disulfide linkages
KR20230093282A (ko) 2020-10-23 2023-06-27 브리스톨-마이어스 스큅 컴퍼니 폐암에 대한 lag-3 길항제 요법
JP2024526122A (ja) * 2021-06-17 2024-07-17 ペットメディックス・リミテッド 抗イヌcd20抗体
JP2024530036A (ja) * 2021-08-06 2024-08-14 ペットメディックス・リミテッド 抗体Fcバリアント
CN119698429A (zh) 2022-06-15 2025-03-25 阿根思有限公司 Fcrn结合分子及使用方法
US20240209096A1 (en) 2022-12-27 2024-06-27 Invetx, Inc. Polypeptides with altered binding to neonatal fc receptor (fcrn) and methods of use
AU2024210302A1 (en) 2023-01-20 2025-09-04 Invetx, Inc. Bispecific binding agents for use in companion animals
EP4656205A1 (en) 2023-01-25 2025-12-03 Nippon Zenyaku Kogyo Co., Ltd. Method for treating canine b cell lymphoma
WO2025121944A1 (ko) * 2023-12-08 2025-06-12 주식회사 박셀바이오 개 cd20을 표적으로 하는 항체, 키메라 항원 수용체 및 이의 용도

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4281061A (en) * 1979-07-27 1981-07-28 Syva Company Double antibody for enhanced sensitivity in immunoassay
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5576195A (en) 1985-11-01 1996-11-19 Xoma Corporation Vectors with pectate lyase signal sequence
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
AU640397B2 (en) 1989-08-25 1993-08-26 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Dog-mouse heterohybridoma and gene fragment coding for constant region of canine immunoglobulin
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
GB9020282D0 (en) 1990-09-17 1990-10-31 Gorman Scott D Altered antibodies and their preparation
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
US5756096A (en) 1991-07-25 1998-05-26 Idec Pharmaceuticals Corporation Recombinant antibodies for human therapy
US6136310A (en) 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
DK0752248T3 (da) 1992-11-13 2000-11-13 Idec Pharma Corp Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
US7744877B2 (en) 1992-11-13 2010-06-29 Biogen Idec Inc. Expression and use of anti-CD20 Antibodies
US5977322A (en) * 1995-06-14 1999-11-02 The Regents Of The University Of California High affinity human antibodies to tumor antigens
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
PT1974747E (pt) 1998-08-11 2012-09-05 Biogen Idec Inc Terapias de combinação para linfomas de células b compreendendo a administração de anticorpo anti-cd20
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
US8119101B2 (en) 1999-05-10 2012-02-21 The Ohio State University Anti-CD74 immunoconjugates and methods of use
US8383081B2 (en) 1999-05-10 2013-02-26 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods of use
US7312318B2 (en) 2002-03-01 2007-12-25 Immunomedics, Inc. Internalizing anti-CD74 antibodies and methods of use
US7829064B2 (en) 1999-05-10 2010-11-09 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods
DE60042785D1 (de) 1999-06-09 2009-10-01 Immunomedics Inc Immuntherapie von autoimmunerkrankungen durch die verwendung von b-zell spezifischen antikörpern
US8501471B2 (en) 2000-10-18 2013-08-06 Sloan-Kettering Institute For Cancer Research Uses of monoclonal antibody 8H9
US8165535B2 (en) 2006-06-04 2012-04-24 Samsung Electro-Mechanics Systems, methods and apparatuses for complementary metal oxide semiconductor (CMOS) antenna switches using switched resonators
WO2003068821A2 (en) 2002-02-14 2003-08-21 Immunomedics, Inc. Anti-cd20 antibodies and fusion proteins thereof and methods of use
US8287864B2 (en) 2002-02-14 2012-10-16 Immunomedics, Inc. Structural variants of antibodies for improved therapeutic characteristics
WO2003089930A1 (en) * 2002-04-22 2003-10-30 Georgetown University Peripheral-type benzodiazepine receptor expression level as an index of organ damage and regeneration
BRPI0315295C1 (pt) 2002-10-17 2021-05-25 Genmab As anticorpo monoclonal humano isolado, célula hospedeira procariótica, composição farmacêutica, molécula biespecífica, usos de um anticorpo, métodos in vitro de detectar a presença de antígeno de cd20 ou uma célula que expressa cd20 em uma amostra, kit, e, vetor de expressão
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
EP1761561B1 (en) 2004-01-20 2015-08-26 KaloBios Pharmaceuticals, Inc. Antibody specificity transfer using minimal essential binding determinants
US20080299546A1 (en) 2004-02-10 2008-12-04 Nihon University Canine Cd20 Gene
US9228008B2 (en) * 2004-05-28 2016-01-05 Idexx Laboratories, Inc. Canine anti-CD20 antibodies
US7531628B2 (en) * 2004-05-28 2009-05-12 Idexx Laboratories, Inc. Canine CD20 compositions
PT2343380T (pt) 2004-11-16 2019-09-18 Humanigen Inc Permuta de cassetes da região variável de imunoglobulina
EP2121756A4 (en) 2006-12-20 2011-08-31 Mmrglobal Inc ANTIBODIES AND PROCESS FOR THEIR PREPARATION AND USE
GB0708002D0 (en) * 2007-04-25 2007-06-06 Univ Sheffield Antibodies
PL3075858T3 (pl) 2007-12-21 2020-07-13 Novartis Ag Ssaczy wektor ekspresyjny
AU2009286956B2 (en) 2008-08-28 2012-12-06 Novartis Ag Cell surface display of polypeptide isoforms by stop codon readthrough
EP2331579B1 (en) * 2008-09-04 2017-07-05 Vet Therapeutics, Inc. Monoclonal antibodies
EP2411050A4 (en) 2009-03-25 2013-07-17 Vet Therapeutics Inc ANTIBODY REGIONS WITH A CONSTANT DOMAIN AND THEIR USE
CA2754408A1 (en) * 2009-03-30 2010-10-14 Boehringer Ingelheim International Gmbh Fusion proteins comprising canine fc portions
WO2010117448A2 (en) * 2009-04-05 2010-10-14 Provenance Biopharmaceuticals Corp. Chimeric immunocytokines and methods of use thereof
US9616120B2 (en) 2010-03-04 2017-04-11 Vet Therapeutics, Inc. Monoclonal antibodies directed to CD20
EP2542258A4 (en) 2010-03-04 2013-08-21 Vet Therapeutics Inc ON CD52 MONOCLONAL ANTIBODIES
WO2011109108A1 (en) * 2010-03-04 2011-09-09 Vet Therapeutics Inc. Monoclonal antibodies directed to cd20
AU2012328819B2 (en) * 2011-10-26 2017-08-03 Elanco Tiergesundheit Ag Monoclonal antibodies and methods of use

Similar Documents

Publication Publication Date Title
JP2014532649A5 (https=)
RU2014120804A (ru) Моноклональные антитела и способы их применения
JP2017501129A5 (https=)
JP2017501130A5 (https=)
JP2012136541A5 (https=)
JP2015526391A5 (https=)
JP2016501839A5 (https=)
FI3442602T3 (fi) Mikrodystrofiinin anto adeno-assioituneella virusvektorilla lihasdystrofian hoitamiseksi
JP2014522236A5 (https=)
JP2023165918A (ja) Hbvワクチン及びhbvを治療する方法
IL308807B2 (en) Combination therapy for treating cancer
JP2018502120A5 (https=)
JP2019508045A5 (https=)
JP2016536314A5 (https=)
JP2014516026A5 (https=)
JP2015007098A5 (https=)
JP2008056679A5 (https=)
JP2014076062A5 (https=)
JP2017524348A5 (https=)
JP2012102122A5 (https=)
JP2010529026A5 (https=)
JP2017514522A5 (https=)
JP2011157378A5 (https=)
JP2018023397A5 (https=)
JP2015522264A5 (https=)